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Abstract 
 
Calcineurin is a Ca(2+)-calmodulin-dependent serine/threonine protein phosphatase involved in many biological 
processes and developmental programmes, including  immune response. One of the most studied substrates of 
calcineurin is the transcription factors NFAT (Nuclear Factor of Activated T cell) responsible for T-cell activation. 
Different anticalcineurin drugs, such as cyclosporine A or FK506, are the most commonly immunosuppressants 
used in transplantation therapies. Unfortunately, their mechanism of action, blocking completely the calcineurin 
phosphatase activity together with the requirement of continuous administration, bears severe side effects. In the 
last years, the family of Regulators of Calcineurin (RCAN) has been described and extensively studied as 
modulators of calcineurin signalling pathways. The RCAN1-1 region, from amino acids 198 to 218, responsible for 
inhibiting in vivo the calcineurin-NFAT signaling pathway has been identified. An RCAN1-derived peptide spanning 
this sequence interferes with the calcineurin-NFAT interaction without affecting the general calcineurin 
phosphatase activity. We report here the development of an optimized in vitro high-throughput fluorescence 
polarization assay based on the disruption of the RCAN1198-218-CnA interaction for identifying molecules with 
immunosuppressant potential. This approach led us to identify dipyridamole as a disruptor of such interaction. 
Moreover, three small molecules with a potential immunosuppressive effect were also identified. 
 
 
Keywords: RCAN1, Calcineurin A, NFAT, immunosuppression, Fluorescence polarization assay, millipolarization 
units, combinatorial libraries. 
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Introduction 
 
Calcineurin (Cn), a calcium and calmodulin 
dependent serine-threonine phosphatase, is an 
heterodimer formed by a catalytic subunit called 
calcineurin A (CnA) and a regulatory subunit called 
calcineurin B (CnB) (Klee 1979). This enzyme 
regulates several biological processes such as heart-
valve morphogenesis, angiogenesis and neural and 
muscle development [2]. In human T cells, Cn 
dephosphorylates the cytoplasmic Nuclear Factors of 
Activated T cells (NFAT) [3] facilitating their 
translocation into the nucleus and consequently 
inititiating the immune response. Currently, 
immunosuppressive protocols used in transplantation 
and treatment of autoimmune diseases are based on 
the administration of calcineurin inhibitors, 
cyclosporine A (CsA) and FK506. Unfortunately, their 
mechanism of action, blocking completely the 
calcineurin phosphatase activity, together with the 
requirement of continuous administration, bears 
severe side effects. Thus, the identification of new 
and more selective molecules with lesser side effects 
than those currently in use is one of the main goals in 
the desired pharmacological control of immune 
response activation. 
     New methods that focus on recent discoveries on 
the molecular mechanism of Cn activity need to be 
devised in order to uncover modulators.  In that 
sense, several endogenous Cn inhibitors such as the 
Regulators of Calcineurin family of proteins (RCAN, 
formerly known as DSCR1 or calcipressins) have 
been identified [8; 12]. Recently, our group has 
demonstrated the in vivo immunosuppressive role of 
human RCAN1 and RCAN3 proteins in human Jurkat 
T lymphocyte cells activated with ionomycin and 
phorbol 12-myristate 13-acetate (PMA) [13; 14]. In 
addition, we have reported on the identification and 
characterization of the RCAN amino acid sequence 
that inhibit  Cn-NFAT signaling in activated Jurkat T 
cells, which in RCAN1 spans from amino acids 198 to 
218 [1]. It is worth noting that a synthetic peptide 
derived from such region (RCAN1198-218) interacts 
with CnA and inhibits the Cn-NFAT signalling without 
affecting general Cn protein phosphatase activity [1]. 
With these antecedents, an in vitro fluorescence 
polarization high-throughput screening assay based 
on the displacement of the interaction between CF-
RCAN1198-218 and CnA was developed leading to the 
identification of dipyridamole as a novel 
immunosuppressive molecule [1]. In the present 
study, we describe in detail such assay and the 
identification of three small molecules that 
significantly displace the RCAN1198-218-CnA 
interaction. 
 
Materials and methods 
 
CnA large scale production  
 
pGEX-6P-1-CnA (human amino acids 2-347) 
plasmid construct was kindly provided by Dr. Patrick 
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Hogan [6]. BL21DE3 E.coli transformed with this 
plasmid was grown in Luria-Bertani medium at 37ºC 
250 rpm. After reaching an optical density of 0.6-0.8 
at 600 nm, GST-CnA production was induced with 
0.5 mM isopropyl-beta-D-thiogalactopyranoside 
(IPTG) (Sigma-Aldrich Co., St Louis, MO) over night 
at 25ºC. Then, cells were centrifuged at 5000xg 10 
min at 4ºC, washed once in PBS supplemented with 
0.5 mM PMSF (Sigma), and centrifuged again. 
Pellets were frozen immediately in dry ice and stored 
at –80ºC. These pellets were resuspended in a lysis 
buffer containing 0.5 mM DTT (Roche Diagnostics, 
IN), 0.2 mM MgCl2, 1 mM EGTA, 2 g/ml aprotinin, 2 
g/ml leupeptin, 2 mM PMSF, 10 g/ml DNase I 
(Roche), 1mg/ml lysozime in PBS and incubated in a 
rotary shaker for 30 min at room temperature. Then, 
samples were sonicated, and after adding 1% triton 
X-100 (v/v), cells were incubated in a rotary shaker 
for 30 min at 4ºC. Finally, samples were subjected to 
three consecutive cycles of freezing at –80ºC and de-
freezing in ice-water. After centrifugation of samples 
at 13.000xg for 30 min at 4ºC total bacterial protein 
extracts were obtained. Then, Glutathione Sepharose 
4B (Amersham Biosciences, Uppsala, Sweden) was 
used for purifying GST-CnA recombinant protein for 4 
h at 4ºC following manufacturer’s instruction. GST-
CnA-Sepharose beads were collected after 
centrifugation and washed in a buffer containing 150 
mM NaCl, 1 mM EDTA, 1 mM DTT, 2 g/ml aprotinin, 
2 g/ml leupeptin, 2 mM PMSF in 50 mM Tris-HCl pH 
7.0 and packed in a column. GST-CnA-Sepharose 
beads were washed twice with ten bed volumes of 
this buffer and eight times more with the same buffer 
without protein inhibitors. Then, GST-CnA-sepharose 
beads were incubated with the PreScissionTM 
Protease (Amersham), which cleaves the specific 
protease cleavage site localized between the GST 
and CnA protein, in a rotary shaker over night at 4ºC. 
The purified CnA fractions were concentrated and 
quantified by spectrometry and protein integrity was 
confirmed by SDS-PAGE.  
 
Peptide synthesis and molecules 
 
The RCAN1198-218 peptide, Ac-Lys-Tyr-Glu-Leu-
His-Ala-Ala-Thr-Asp-Thr-Thr-Pro-Ser-Val-Val-Val-
His-Val-Cys-Glu-Ser-NH2, its N-terminal 
carboxyfluorescein (CF) derivative, the labeled CF-
control peptide, CF-Gly-Gly-Met-Ala-Gly-Pro-His-Pro-
Val-Ile-Val-Ile-Thr-Gly-Pro-His-Glu-Glu- NH2 and the 
unlabeled control peptide, Ac-Ser-Ala-Val-Thr-His-
Lys-Leu-Glu-Ser-Val-Asp-Pro-Ala-Thr-Val-Tyr-Cys-
Glu-Thr-His-Val- NH2. were synthesized as 
previously described [1]. MALDI-TOF mass 
spectrometry in a 4700 Proteomics Analyzer (Applied 
Biosystems, Foster City, CA) was used to confirm 
peptide identity. Several libraries of peptides and 
small molecules were screened to identify disruptor 
candidates of the CF-RCAN1198-218-CnA interaction: a 
hexapeptide-based library, a diversity-oriented 
positional scanning library of N-alkylglycine trimers 
[15] and the Prestwick Chemical Library®.  
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All molecules diluted in 10% (v/v) DMSO in water 
were first analyzed in the assay at 100 M. Only 
those compounds promoting a displacement of the 
CF-RCAN1198-218-CnA interaction higher than 45% 
were further assayed to evaluate their effect in a 
dose-dependent manner in the same assay. 
 
MALDI-TOF mass spectrometry 
 
2.5 M CnA was incubated in the absence or 
presence of 25 M CF-RCAN1198-218 peptide in PBS, 
in a final volume of 100 l. Reactions were incubated 
for 15 min, 250 rpm at 25ºC. After adding 0.37% 
formaldehyde, samples were incubated 10 min more 
in the same assay conditions. Finally, reactions were 
stopped by adding 125 mM glycine. Samples were 
identified by MALDI-TOF mass spectrometry and 
data obtained were analyzed using the Data Explorer 
4.5 software (Applied Biosystems). 
 
Fluorescence polarization binding assay 
 
The CF-RCAN1198-218-CnA interaction was 
analyzed in black 96-well flat bottom plates 
(OptiPlate-96F(PB), Perkin Elmer) using a 
WallacVictor2 1420 Multilabel HTS counter 
(PerkinElmer) and the Wallac 1420 Manager 
software. Parameters of the program used were as 
follows: excitation wavelength 480 nm, observed 
emission wavelength 535 nm, normal polarizer 
aperture, 0.1 s counting time and 1.2 Factor G 
Results obtained, indicated in millipolarization units 
(mP), were calculated with the following equation: 
                               (Ipa-1.2xIpe)    
             mP= 103x          
                              (Ipa+1.2xIpe) 
                                                                     
Ipa and  Ipe, correspond to the intensity of the paralel 
and perpendicular emitted light, respectively. The 
optimal binding protocol was obtained by adding 30 
nM of CF-RCAN1198-218 peptide to 200 l of PBS (pH 
7.4) containing increasing amounts of CnA for 15 min 
at room temperature. 0.01% (wt/vol) fraction V bovine 
serum albumin (BSA) (Roche) was added to the 
assay. To analyze the ability to displace the CF-
RCAN1198-218-CnA interaction, molecules were 
incubated for 15 min at room temperature with 1.5 
M CnA with the aim of facilitating their interaction, 
and then 30 nM CF-RCAN1198-218 peptide was added 
to the assay. The final DMSO concentration in all the 
experiments was below 2% (v/v).  
 
Results  
 
The RCAN proteins play an immunosuppressive 
role in  the human T lymphocyte Jurkat cell line by 
inhibiting the Cn-NFAT signalling pathway in vivo [13; 
14]. As mentioned before, the identification of the 
RCAN1 sequence responsible for its biological role 
[1] tempted us to evaluate whether a RCAN1-derived 
peptide (RCAN1198-218) spanning such amino acidic 
sequence could be a useful tool for identifying novel 
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molecules with immunosuppressant therapeutic 
potential. With this aim, we decided to set up and 
optimize an in vitro assay for analyzing the interaction 
between the RCAN1198-218 peptide and CnA taking 
advantage of the fluorescence polarization 
technology. 
First, we evaluated the behavior of a 
carboxifluorescein labelled RCAN1198-218 peptide (CF-
RCAN1198-218) in 96-well plates in fluorescence 
polarization-based experiments in the absence of 
CnA (Fig. 1). We detected a high background when 
compared with a non-related carboxifluorescein 
labelled control peptide (Fig. 1, compare black bar in 
CF-RCAN1198-218 peptide vs CF-control peptide). This 
result suggests that the CF-RCAN1198-218 peptide has 
tendency to self-aggregate in solution or alternatively 
it becomes immobilized to the assay plates. To 
overcome this problem, we evaluated the efficiency 
of different blocking agents in the assay buffer. We 
tested two different reagents: 10% of immunoglobulin 
(IgG) and 1% of bovine fraction V serum albumin 
(BSA) (Figure 1, compare white bar and grey bar, 
corresponding to IgG and BSA, respectively, vs black 
bar, which represents absence of blocking agent). 
Our results show that adding blocking agents 
significantly reduces the background of the 
fluorescence polarization values obtained with the 
CF-RCAN1198-218 peptide alone. Further 
characterization of the CF-RCAN1198-218 peptide-CnA 
interaction was performed supplementing the assay 
with BSA. 
In order to study the interaction between the CF- 
RCAN1198-218 peptide and CnA we performed titration 
curves at a constant CF-RCAN1198-218 peptide 
concentration (30 or 60 nM) and increasing CnA 
concentrations (in a range from 0.01 to 10 M). In 
both cases, the CF-RCAN1198-218-CnA interaction is 
established with similar efficiency and the polarization 
units increase in a CnA-dependent manner 
confirming the specificity of such interaction. Both 
conditions evaluated showed comparable 
millipolarization values (Fig. 2A). Thus, a 30 nM 
concentration of CF-RCAN1198-218 peptide was 
routinely used in the assay. Furthermore, the actual 
binding of the RCAN1198-218 peptide to CnA was also 
confirmed by peptide-protein crosslinking followed by 
mass spectrometry (MALDI-TOF) analysis (Fig. 2B). 
In the absence of the RCAN1198-218 peptide or when 
CnA was incubated with the crosslinker agent and an 
unlabeled control peptide, the mass spectrum 
obtained showed only one peak corresponding to 
free CnA, which molecular mass is 41 kDa (Fig. 2B, 
see CnA and CnA-control peptide corresponding 
graphs).  However, when CnA in presence of the 
RCAN1198-218 peptide was crosslinked a second peak 
appeared in the mass spectrum, which total mass 
corresponds to the complex between RCAN1198-218 
peptide and CnA, which total molecular mass is 43 
kDa (Fig. 2B, see RCAN1198-218-CnA corresponding 
graph). 
Next, we evaluated the steady-state optimal 
conditions for the CF-RCAN1198-218-CnA interaction-
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based assay. As depicted in Fig. 3A the 
millipolarization values obtained were constant after 
15, 30 or 60 min at room temperature suggesting the 
formation of an stable complex after 15 min. The 
stabilization of a protein-protein or a peptide/protein 
interaction has a strong hydrophobic component 
arising from the interaction between the two large 
amino acidic surfaces provided. Then these 
complexes are sensitive to the presence of the 
organic solvents (DMSO is the preferred cosolvent) 
that usually contain the chemical libraries.  Then, the 
DMSO concentration allowed by the CF-RCAN1198-
218-CnA interaction was analyzed and turned out to 
be very sensitive being the maximum DMSO 
concentration allowed at the assay only 2% (Fig 3B).  
Once optimized all the parameters of the CF-
RCAN1198-218-CnA interaction in the in vitro 
fluorescence polarization assay, binding parameters 
for the CF-RCAN1198-218 peptide were determined 
performing titration curves until reaching saturation. 
The results obtained showed that the Kd (dissociation 
constant) for the RCAN1198-218 peptide is 1.25±0.09 
M and the IC50 is 3.72 ±0.28 M[1]. This fact, 
together with the relative large millipolarization units 
increase shown (from 45-195 mP) and the small 
standard deviation obtained (less than 5%) has 
permitted us to develop a robust in vitro assay. 
Different libraries composed by peptides or small 
molecules were used in order to identify molecules 
capable of disrupting the CF-RCAN1198-218-CnA 
interaction, among them, the Prestwick Chemical 
Library®. This library includes 880 biologically active 
compounds with high chemical and pharmacological 
diversity. An initial screening assay leads us to 
identify some hit compounds that were also analyzed 
in a dose dependent manner to confirm their efficacy 
(Fig. 4). Table 1 summarizes the characteristics of 
the hit candidates analyzed. Further in vivo 
characterization of the most efficient molecule, 
dypiridamole, which is clinically used as an 
antiplatelet agent to prevent heart stroke, has 
revealed a previously unreported 
immunosuppressant role for this molecule [1]. Taken 
together, these results demonstrate that the in vitro 
assay here described is a useful tool for identifying 
novel molecules with in vivo immunosuppressive 
effect. 
   
Discussion 
 
Nowadays, immunosuppressive protocols used in 
transplantation and treatment of autoimmune 
diseases include always the use of calcineurin 
inhibitors due to the pivotal role of this enzyme in the 
activation of the immune response. Unfortunately, the 
multiple and severe side effects that their long-life 
administration produces, cancer, nephrotoxicity and 
neurotoxicity, makes necessary finding novel 
effective and less toxic agents. With this aim, Roehrl 
et al. developed an in vitro assay based on the 
interaction established between CnA and the VIVIT 
peptide [6], which inhibits NFAT signaling. The VIVIT 
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peptide amino acid sequence was selected from the 
natural SPRIEIT sequence on NFAT1 due to its high 
affinity binding to Cn [4]. Frim this assay, several 
immunosuppressant small molecules were identified 
in the Roehrl’s assay, called INCA. Unfortunately, 
most of those molecules were reactive quinones that 
promoted severe cytotoxic effects to all evaluated cell 
Unfortunately, the in vivo use of these molecules in 
cell lines revealed a strongly high cytotoxicity due to 
their quinone structure [6]. Thus, we decided to direct 
our discovery efforts in finding new 
immunosuppresants towards the novel RCAN1-CnA 
interaction recently described [8]. Our results 
demonstrate that the RCAN1198-218 peptide binds to 
CnA with high affinity and more importantly, this 
peptide inhibits Cn signaling towards NFAT, thereby 
preventing NFAT from being activated, without 
affecting general Cn phosphatase activity [1]. In this 
direction, we have recently shown that the RCAN1198-
218 peptide interfere with the SPRIEIT sequence on 
NFAT for binding to Cn. Thus, considering its 
biochemical properties together with its specific 
mechanism of inhibition towards the Cn-NFAT 
signalling, the RCAN1198-218 peptide arises as an 
alternative and efficient tool for identifying novel 
immunosuppressive molecules. More importantly, its 
specific mechanism of inhibition towards the Cn-
NFAT signalling indicates that the molecules 
identified might be also specific for the Cn-NFAT 
pathway in cultutred T cells. 
With this aim, we set up and optimize the first in 
vitro fluorescence polarization-based assay targeting 
the interaction between the RCAN1198-218 peptide and 
CnA. The results here presented indicate that this 
assay is specific, fast, highly reproducible, robust and 
could be easily standarized for high throughput 
screening analysis. As a consequence, it will 
increase the number of hit candidates that in turn will 
offer new possibilities aside from those molecules 
that promoted a total displacement of the Cn-NFAT 
interaction. Up to the present time, our group has 
evaluated dypiridamole as one compound identified 
from a chemical library using such an assay. The 
specific inhibitory capacity of dipiridamole obtained in 
in vivo experiments confirms the effectiveness of the 
assay in identifying novel immunossuppressive drugs 
[1]. Further structural analysis are ongoing to identify 
in detail the mechanism used by dipyridamole for 
disrupting the RCAN1-CnA interaction.  
Furthermore, the data here presented increase the 
number of hit candidates with three new molecules 
with putative immunosuppressant role: coralyne 
chloride hydrate, daunorubicin hydrochloride and 
chicago sky blue 6B (Fig. 4). On one side, coralyne 
chloride hydrate and daunorubicin hydrochloride are 
drugs clinically used as antileukemic agents [16; 17]. 
On the other side, Chicago sky blue 6B is a potent 
inhibitor of L-glutamate uptake into synaptic vesicles 
[18] and recently it has been described that is an 
inhibitor of the Ca2+/calmodulin-dependent protein 
kinase phosphatase family but not of calcineurin [19]. 
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Thus, to date there is no evidence suggesting the 
existence of a novel immunossuppressive role for 
any of these three compounds. In a similar manner 
as it has been described for dipyridamole [1], we 
expect to further confirm their in vivo inhibitory effect 
towards the Cn-NFAT signalling pathway using cell 
lines as well as animal models.  
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FIGURE LEGENDS 
 
 
Table 1. Summary of the molecules with immunosuppressant potential responsible for disrupting the CF-RCAN1198-
218 -CnA interaction identified from the Prestwick Chemical Library® 
 
Fig. 1. Determination of the CF-RCAN1198-218 peptide fluorescence background in the fluorescence polarization 
assay. The CF-RCAN1198-218 peptide or a control non-related carboxyfluoresceinated peptide were incubated in the 
assay with no blocking agent (black bars) or in presence of two different blocking agents: 10% IgG (white bars) or 
1% BSA (grey bars), respectively. The graphs show the mean  SD of three independent experiments performed in 
triplicate. 
 
Fig. 2. The CF-RCAN1198-218 peptide interacts with CnA. A. Determination of the optimal CF-RCAN1198-218 peptide 
concentration required to achieve the higher difference between the minimal and the maximum millipolarization 
values. Titration experiments were performed fixing the CF-RCAN1198-218 peptide concentration (30 or 60 nM) in 
presence of increasing CnA concentrations (from 0.01 to 10 M). Experiments were performed three times in 
triplicate. B. Evaluation of the RCAN1198-218-CnA interaction by peptide-protein crosslinking followed by mass 
spectrometry (MALDI-TOF) analysis. Left panel corresponds to the assay including CnA alone; central panel 
corresponds to the assay including RCAN1198-218 and CnA; right panel corresponds to the assay including an 
unlabeled RCAN non-related peptide together with CnA. CnA molecular mass is approximately 41 kDa; RCAN1198-
218 and Control peptides molecular mass is approximately 2.2 kDa. 
 
Fig. 3. Characterization of the optimal assay conditions for the CF-RCAN1198-218-CnA interaction. A. 15 min of 
incubation for a sample containing CF-RCAN1198-218 and CnA is sufficient for the protein-protein interaction to take 
place. White bars correspond to free CF-RCAN1198-218 peptide whereas black bars correspond to the CF-RCAN1198-
218-CnA established interaction. B. DMSO concentration above 2% affects the CF-RCAN1198-218-CnA fluorescence 
polarization assay. White bars correspond to the free CF-RCAN1198-218 peptide whereas black bars correspond to 
the CF-RCAN1198-218-CnA. All experiments were performed twice in triplicate. 
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Fig. 4.  Dose-dependent analysis of disruptors of the CF-RCAN1198-218-CnA interaction identified from screening the 
Prestwick Chemical Library® by the fluorescence polarization assay.  Data shown correspond to three independent 
experiments performed in triplicate. 
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